POAG surgical outcomes affected by DM

Article

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

Dr Simon K. Law, Glaucoma Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA, studied 41 eyes of 29 patients with DM and 81 eyes of 64 patients without DM. Patients with DM without retinopathy were retrospectively compared with a control group without DM. Surgical success was defined as IOP ≤15 and >5 mmHg without complications or further glaucoma surgery.

At 60 months the Kaplan–Meier cumulative survival rates were 57.8±9.3% for the DM group and 68.6±5.3% for the control group. Mean postoperative IOP of the control group was statistically significantly lower than the DM group at the two, three, six and seven-year follow-up visits. The rates of postoperative complications and additional glaucoma surgeries were the same between the two groups.

POAG patients with DM without retinopathy undergoing primary trabeculectomy with MMC could have a lower long-term surgical survival rate, compared to patients without DM.

The abstract can be read in the latest issue of the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.